Maiden Pharmaceuticals: Gambia cough syrup scandal

General
1

The Maiden Pharmaceuticals Gambia cough syrup scandal involved the deaths of around 70 children in The Gambia between July and October 2022, linked to four cough syrups manufactured by India’s Maiden Pharmaceuticals.

The content of cough syrup includes diethylene glycol (DEG) and ethylene glycol (EG) which are harmful toxic to humans and could be fatal if consumed.

Due to consumption of these contaminated syrups led to fatal kidney injuries, accounting for at least 66–70 confirmed child deaths in the Gambia.

This his raises a big question about pharmaceutical regulation, quality control, and cross-national supply chain safety regarding medicines, especially to low- and middle-income countries. It also triggered heightened scrutiny of India’s pharmaceutical export practices after similar cases in other countries.

MBH/AB

1 Like
2

It is necessary to adopt strict regulations for the export of Drugs to prevent the occurance of such cases. Thankyou for sharing.

1 Like
3

This highlights how important strict quality check and retrospection is. This happens with several pharmaceutical companies. Although not everytime the result is the same, but the quality of medicines being exported to developing or under-developed countries are mostly compromised.

1 Like